Hovione Commits to Science-Based Targets for Greenhouse Gas (GHG) Emissions
Hovione commitment to setting SBTs in line with the Paris Agreement
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Hovione commitment to setting SBTs in line with the Paris Agreement
Pharmaceutical Technology, 2 Junho 2021
Scientist Live, 12 May 2025
Innovation potential in profitable growth and financial strength
Les Echos, 2 December 2025
Make your drug soluble with Dispersome® technology. Dispersome® is a solubility enhancement technology that relies on an innovative and naturally occurring excipient to develop amorphous solid dispersions with high drug loading and high bioavailability.
Hovione is proud to announce the opening of a state-of-the-art continuous tableting (CT) line at its R&D Center in Lisbon.